Q-omics provides the consensus-scored KIAA1210 profile across patient tissues and cancer cell-line models. KIAA1210 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, KIAA1210 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, KIAA1210 RNA expression shows 9,374 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight SCLC, KIRC, and PAAD as cancer lineages where KIAA1210 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIAA1210 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIAA1210 survival associations across molecular data types. KIAA1210 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIAA1210 RNA expression–survival associations across cancer types. High KIAA1210 expression shows unfavorable associations in BLCA and LIHC, but favorable associations in SCLC, KIRC, LUAD and UCEC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify SCLC as the clearest survival context for KIAA1210 RNA expression.
This table summarizes KIAA1210 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KIAA1210. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIAA1210 shows lower tumor expression in KIRC, UCEC, KIRP and BLCA and higher tumor expression in COAD and HNSC. The KIRC box plot shows higher KIAA1210 RNA expression in normal versus tumor tissue (log2 FC = −0.296, t-test p < 0.001).
This table shows molecular features associated with KIAA1210 in patient tissues and cancer cell lines. In patient samples, KIAA1210 shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set. In cancer cell lines, KIAA1210 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
